DK2273994T3 - PHARMACEUTICAL FORMS OF A MEDICINE - Google Patents

PHARMACEUTICAL FORMS OF A MEDICINE Download PDF

Info

Publication number
DK2273994T3
DK2273994T3 DK09726748.8T DK09726748T DK2273994T3 DK 2273994 T3 DK2273994 T3 DK 2273994T3 DK 09726748 T DK09726748 T DK 09726748T DK 2273994 T3 DK2273994 T3 DK 2273994T3
Authority
DK
Denmark
Prior art keywords
ene
crystalline
triol
ethynyl
androst
Prior art date
Application number
DK09726748.8T
Other languages
Danish (da)
English (en)
Inventor
Steven K White
Igor Ivanisevic
Mark Andres
Kyle Stephens
Brenton Wolf
Original Assignee
Neurmedix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurmedix Inc filed Critical Neurmedix Inc
Application granted granted Critical
Publication of DK2273994T3 publication Critical patent/DK2273994T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
DK09726748.8T 2008-04-03 2009-04-03 PHARMACEUTICAL FORMS OF A MEDICINE DK2273994T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4224008P 2008-04-03 2008-04-03
PCT/US2009/039567 WO2009124300A2 (en) 2008-04-03 2009-04-03 Solid state forms of a pharmaceutical

Publications (1)

Publication Number Publication Date
DK2273994T3 true DK2273994T3 (en) 2016-02-01

Family

ID=41136126

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09726748.8T DK2273994T3 (en) 2008-04-03 2009-04-03 PHARMACEUTICAL FORMS OF A MEDICINE

Country Status (13)

Country Link
US (9) US8252947B2 (enExample)
EP (1) EP2273994B1 (enExample)
JP (2) JP2011527986A (enExample)
KR (1) KR101545300B1 (enExample)
CN (1) CN102215845A (enExample)
AU (1) AU2009231589B2 (enExample)
CA (1) CA2728889C (enExample)
DK (1) DK2273994T3 (enExample)
ES (1) ES2562069T3 (enExample)
HU (1) HUE028337T2 (enExample)
PL (1) PL2273994T3 (enExample)
PT (1) PT2273994E (enExample)
WO (1) WO2009124300A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009124300A2 (en) * 2008-04-03 2009-10-08 Hollis-Eden Pharmaceuticals, Inc. Solid state forms of a pharmaceutical
US8309746B2 (en) 2008-06-06 2012-11-13 Harbor Therapeutics, Inc Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds
WO2012083161A1 (en) * 2010-12-17 2012-06-21 Harbor Biosciences, Inc. Steroid tetrol solid state forms
CN103768071B (zh) * 2012-10-23 2016-08-17 中国医药工业研究总院 一种治疗糖尿病的口服制剂
WO2019041078A1 (en) * 2017-08-28 2019-03-07 Zhejiang Jiachi Pharmaceutical Development Ltd. ASYMMETRIC SYNTHESIS AND USES OF COMPOUNDS IN TREATMENT OF DISEASES
JP2024519079A (ja) * 2021-05-18 2024-05-08 バイオビー・インコーポレイテッド 神経変性状態の治療のための組成物
WO2024054452A1 (en) * 2022-09-06 2024-03-14 Biovie Inc. Methods for the treatment of mild cognitive impairment
CN120484042A (zh) * 2025-05-16 2025-08-15 中国人民解放军军事科学院军事医学研究院 一种he3286的合成方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329366A (en) * 1979-11-08 1982-05-11 Johnson & Johnson Products, Inc. Topical acylaminophenols
US4898694A (en) * 1987-11-25 1990-02-06 Schwartz Arthur G 17-Hydroxy-steroids
DE3801229A1 (de) 1988-01-18 1989-07-27 Krupp Polysius Ag Mahlverfahren sowie mahlanlage
JP2642486B2 (ja) 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5292730A (en) * 1990-08-29 1994-03-08 Humanetics Corporation Modulation of immune system with Δ5-androstenes
ATE227992T1 (de) * 1990-08-29 2002-12-15 Humanetics Corp Behandlungsverfahren zur förderung des gewichtsverlustes unter verwendung eines substituierten delta-5-androstens
US5641766A (en) * 1990-08-29 1997-06-24 Humanetics Corporation UP-regulation of immune system with Δ 5-Androstenes
US5271944A (en) 1991-04-05 1993-12-21 Biofor, Ltd. Pharmacologically enhanced formulations
US5922701A (en) * 1992-05-01 1999-07-13 University Of Utah Research Foundation Method for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue
US5424077A (en) 1993-07-13 1995-06-13 Church & Dwight Co., Inc. Co-micronized bicarbonate salt compositions
TW369521B (en) 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
US5455049A (en) 1995-01-04 1995-10-03 Ascent Pharmaceuticals, Inc. Terfenadine oral powder
US5859000A (en) * 1995-06-07 1999-01-12 University Of Utah Research Foundation Method for reducing mast cell mediated allergic reactions
US6686486B1 (en) * 1997-05-07 2004-02-03 Padma Marwah Process for effecting allylic oxidation
US5869709A (en) * 1997-05-07 1999-02-09 Humanetics Corporation Process for effecting allylic oxidation
ZA986614B (en) * 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
AU3088799A (en) * 1998-03-18 1999-10-11 Humanetics Corporation Process for effecting allylic oxidation using dicarboxylic acid imides and chromium reagents
US20070129282A1 (en) * 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
US20030060425A1 (en) * 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
US20080015174A1 (en) * 1998-11-24 2008-01-17 Reading Christopher L Metabolic Disease Treatments
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US20060079492A1 (en) * 1999-10-25 2006-04-13 Ahlem Clarence N Compositions and treatment methods
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US7045513B1 (en) * 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
CA2669753C (en) * 1999-09-30 2012-06-26 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
CA2388939C (en) 1999-10-25 2009-06-09 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatments for blood cell deficiencies
US6274746B1 (en) * 2000-08-30 2001-08-14 Padma Marwah Process for allylic oxidation using metal hypochlorite and alkyl hydroperoxide
SK288222B6 (sk) * 2000-12-14 2014-09-04 Ortho-Mcneil Pharmaceutical, Inc. Steroidné hormonálne prípravky a spôsoby ich prípravy
FR2820745A1 (fr) * 2001-02-14 2002-08-16 Oreal Procedes de preparation de la 7alpha-hydroxy- dehydroepiandrosterone
WO2003043570A2 (en) * 2001-11-15 2003-05-30 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
AU2003261380A1 (en) 2002-08-06 2004-02-23 Ssci, Inc. Method of comparing x-ray diffraction patterns using the fundamental parameter method
EP1678484A2 (en) 2003-10-27 2006-07-12 SSCI, Inc. Method for monte carlo indexing of powder diffraction data
US20070243620A1 (en) 2004-02-24 2007-10-18 Simon Bates Analysis and Screening of Solid Forms Using the Atomic Pair Distribution Function
CA2582231A1 (en) * 2004-09-29 2006-10-19 Hollis-Eden Pharmaceuticals, Inc. Steroid analogs and uses
US20060073099A1 (en) * 2004-10-01 2006-04-06 Frincke James M Treatment screening methods
US20060211604A1 (en) * 2004-11-26 2006-09-21 The Brigham And Women's Hospital, Inc. Methods for treating inflammatory disorders using regulators of microvessel dilations
US7964604B2 (en) * 2005-02-18 2011-06-21 Solvay Pharmaceuticals B.V. Bifeprunox mesylate maintenance dose compositions and methods for using the same
PL2012773T3 (pl) 2006-04-22 2012-12-31 Harbor Biosciences Inc Leki i zastosowania
US20080153792A1 (en) * 2006-11-17 2008-06-26 Frincke James M Drug Identification and Treatment Method
US8354396B2 (en) * 2006-11-17 2013-01-15 Harbor Therapeutics, Inc. Drug identification and treatment method
US8217025B2 (en) * 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
US20080221074A1 (en) * 2006-11-17 2008-09-11 Jaime Flores-Riveros Drug Screen and Treatment Method
DE102007054497B3 (de) * 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
EP2249838A4 (en) * 2008-02-05 2012-05-02 Harbor Biosciences Inc Pharmaceutical solid state forms
WO2009124300A2 (en) 2008-04-03 2009-10-08 Hollis-Eden Pharmaceuticals, Inc. Solid state forms of a pharmaceutical
US8309746B2 (en) * 2008-06-06 2012-11-13 Harbor Therapeutics, Inc Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds
US20100075937A1 (en) * 2008-09-24 2010-03-25 Hollis-Eden Pharmaceuticals, Inc. Patient populations and treatment methods
US9310310B2 (en) 2011-08-26 2016-04-12 3M Innovative Properties Company Flowable dry powder composition

Also Published As

Publication number Publication date
US20200190133A1 (en) 2020-06-18
US20090291933A1 (en) 2009-11-26
CN102215845A (zh) 2011-10-12
US20160083415A1 (en) 2016-03-24
US20160175322A9 (en) 2016-06-23
CA2728889A1 (en) 2009-10-08
WO2009124300A3 (en) 2011-06-23
US20120302537A1 (en) 2012-11-29
US20120296105A1 (en) 2012-11-22
US9555046B2 (en) 2017-01-31
US8252947B2 (en) 2012-08-28
EP2273994A4 (en) 2012-05-30
US10995112B2 (en) 2021-05-04
PT2273994E (pt) 2016-03-15
AU2009231589A1 (en) 2009-10-08
KR101545300B1 (ko) 2015-08-18
HUE028337T2 (en) 2016-12-28
EP2273994A2 (en) 2011-01-19
US20180208623A1 (en) 2018-07-26
US20160045516A1 (en) 2016-02-18
US20220002338A1 (en) 2022-01-06
JP2011527986A (ja) 2011-11-10
US9850271B2 (en) 2017-12-26
KR20100132539A (ko) 2010-12-17
ES2562069T3 (es) 2016-03-02
JP2015042686A (ja) 2015-03-05
EP2273994B1 (en) 2015-12-02
WO2009124300A2 (en) 2009-10-08
CA2728889C (en) 2016-06-14
AU2009231589B2 (en) 2013-11-07
PL2273994T3 (pl) 2016-05-31
US9877972B2 (en) 2018-01-30
US20170152281A1 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
US10995112B2 (en) Crystalline solvate forms of a pharmaceutical
US11136306B2 (en) Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-peridine-2,6-dione
HK1157679A (zh) 藥學試劑的固體形式
HK1147695B (en) Pharmaceutical solid state forms
AU2012200259A1 (en) Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione